Open AccessIn Vitro Activity of Gepotidacin against Gram-Negative and Gram-Positive Anaerobes
Author(s) -
Meredith Hackel,
James A. Karlowsky,
Michele A. Canino,
Daniel F. Sahm,
Nicole E. Scangarella-Oman
Publication year - 2022
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.02165-21
Subject(s) - gram , microbiology and biotechnology , agar dilution , anaerobic exercise , gram negative bacteria , gram positive bacteria , in vitro , biology , antibacterial activity , agar dilution method , agar , bacteria , anaerobic bacteria , antibiotics , minimum inhibitory concentration , escherichia coli , biochemistry , physiology , genetics , gene
Gepotidacin (formerly GSK2140944) is a first-in-class triazaacenaphthylene antibacterial currently in phase III clinical trials. When tested against Gram-negative (n = 333) and Gram-positive (n = 225) anaerobes by agar dilution, gepotidacin inhibited 90% of isolates at concentrations of 4 and 2 μg/mL, respectively.